Israel’s Metabomed is developing treatments using small molecules that target and inhibit metabolic enzymes vital for cancer cells’ survival. It currently has four pipeline programs. Metabomed has just raised a further $12.5 million of funds to help it prepare for clinical trials.
https://www.calcalistech.com/ctech/articles/0,7340,L-3776158,00.html